Foundayo and Wegovy pill comparison brief overview Foundayo (orforglipron, by Eli Lilly) and the Wegovy pill (oral semaglutide, by Novo Nordisk) are both once-daily GLP-1 receptor agonist tablets approved for chronic weight management in adults with obesity or overweight
Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle
GLP-1 agonists are pricey
Additionally, rapid weight loss in older adults can lead to loss of lean muscle mass (sarcopenia), which may impact functional status and increase fall risk
When meals shrink, protein gets missed, fluids slip, and nausea or constipation nudges you toward bland bites and long gaps, your body simply has less usable energy to run on
it is a structural feature of the evidence base